10-Q - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

10-Q - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

144 - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

144 - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

144 - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

144 - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

144 - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients with acquired resistance and intrinsic driver EGFR mutations Confirmed radiographic partial response by RECIST 1.1 achieved across predicted therapeutic doses in 5 of 12 NSCLC patients in subgroup with measurable disease, who underwent post baseline tumor assessment by RECIST1.1; one additional patient demonstrated unconfirmed PR awaiting confirmation, while the remaining six patients had stable diseaseExpansion cohorts expected to commence i

Piper Sandler analyst Joseph Catanzaro maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Overweight and maintains $12 price target.

Gainers Elutia (NASDAQ:ELUT) stock rose 24.2% to $4.31 during Tuesday's regular session. The market value of their outstanding shares is at $104.9 million. Trinity Biotech (NASDAQ:TRIB) stock rose 20.61% to $2.75. The company's market cap stands at $26.0 million. Akari Therapeutics (NASDAQ:AKTX) shares moved upwards by 20.26% to $3.03. The company's market cap stands at $35.5 million. Kronos Bio (NASDAQ:KRON) shares increased by 16.71% to $1.11. The market value of their outstanding shares is at $66.7 million. Black Diamond Therapeutic (NASDAQ:BDTX) shares increased by 15.72% to $5.91. The market value of their outstanding shares is at $332.7 million. Streamline Health Solns (NASDAQ:ST

HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11 price target.

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 "trigger" ("window of opportunity") investigator-sponsored trial demonstrated BDTX-1535 achieved clinically meaningful drug levels in brain tumor tissue

HC Wainwright & Co. analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and lowers the price target from $12 to $11.

Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.44) by 20.45 percent.

Gainers 180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NASDAQ:ABVC) shares rose 5.22% to $1.42. The company's market cap stands at $15.0 million. Medpace Hldgs (NASDAQ:MEDP) stock increased by 5.15% to $427.5. The company's market cap stands at $13.2 billion. The company's, Q1 earnings came out yesterday. Adverum Biotechnologies (NASDAQ:ADVM) stock increased by 5.0% to $11.55. The market value of their outstanding shares is at $239.7 million. Black Diamond Therapeutic (NASDAQ:BDTX) stock moved upwards by 4.99% to $5.26. The market value of their

Wedbush analyst Robert Driscoll maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and raises the price target from $10 to $16.

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting characterized by shorter duration of response to osimertinib BDTX-1535 profile differentiated as the most advanced fourth-generation oral TKI in clinical development addressing the full spectrum of classical, non-classical, and C797S resistance EGFR mutations

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be

CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company's Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These changes became effective as of April 10, 2024. "On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncolog

Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024BDTX-1535 Phase 1 dose escalation data in GBM expected later this yearDosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors Cash, cash equivalents, and investments of $144.3 million as of September 30, 2023, expected to be sufficient to fund operations into the fir

Presented new data at the 34th EORTC-NCI-AACR Symposium highlighting robust preclinical anti-tumor activity of BDTX-1535 and BDTX-4933 across multiple families of oncogenic mutations while sparing wild type; both MasterKey therapies demonstrate key attributes of next generation small molecule inhibitorsOn track to provide a clinical update on BDTX-1535 in 2023 and to file an IND for BDTX-4933 in the first half of 2023Strengthened clinical development leadership with appointment of Melanie Morrison as Senior Vice President, Development Operations, who brings over two decades of experience in oncology drug developmentCash, cash equivalents and investments of approximately $144.2 million as of

Strengthened leadership team with appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical OfficerAdvanced MasterKey therapy pipeline with first patient dosed in Phase 1 global study of BDTX-1535, and continued IND-enabling studies of BDTX-4933Cash, cash equivalents and investments of approximately $160.9 million as of June 30, 2022; expected to be sufficient to fund operations into the third quarter of 2024 CAMBRIDGE, Mass. and NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the second quarter ended Jun

CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Wendy L. Dixon, Ph.D., to its Board of directors. Additionally, Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures and a member of Black Diamond's Board of Directors since 2017, has resigned from the Board. "Brad's contributions to Black Diamond over the last five years have been invaluable. He has supported the company from its founding through many stages of our development including our path to becoming a public comp

CAMBRIDGE, Mass. and NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Elizabeth Montgomery as its first Chief People Officer. Ms. Montgomery brings almost 20 years of global human resources leadership experience in the life sciences industry. In the newly created role, Ms. Montgomery will be a key member of the executive leadership team and have responsibility for the development and execution of Black Diamond's people and talent strategy. "We are thrilled to welcome Elizabeth to the Black Diamond executive tea

Initial Phase 1 clinical PK, safety, and preliminary efficacy data for BDTX-189 presented at ASCO Annual Meeting; on track to initiate Phase 2 portion of MasterKey-01 study in second half of 2021Pre-clinical data for BDTX-1535 presented at AACR Annual Meeting; program on track to enter the clinic in 2022Early-stage pipeline programs targeting BRAF and FGFR remain on track for IND filing in 2022Biotech industry veteran Mark Velleca, M.D., Ph.D., appointed to Board of DirectorsCash, cash equivalents, and investments of $263.5 million as of June 30, 2021, expected to be sufficient to fund operations into 2023 CAMBRIDGE, Mass. and NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Black Diamond Ther

CAMBRIDGE, Mass. and NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the appointment of Mark A. Velleca, M.D., Ph.D. to its Board of Directors. Dr. Velleca brings over 20 years of leadership experience in the biotechnology industry, particularly in the field of oncology, most recently serving as Chief Executive Officer of G1 Therapeutics. "I am delighted to welcome Mark to the Black Diamond Board of Directors," said Robert A. Ingram, Chairman of the Board of Directors of Black Diamond Therapeutics. "Mark brings s

CAMBRIDGE, Mass. and NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Dr. Kapil Dhingra to its Board of Directors. Dr. Dhingra has more than 30 years’ experience in oncology clinical research and drug development, including as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at Hoffmann-La Roche (“Roche”). He has served as a clinical and strategic advisor to Black Diamond since 2017. “I am delighted to welcome Kapil to the Black